Study design (if review, criteria of inclusion for studies)
Retrospective case-control study
Participants
13 patients with a confirmed diagnosis of CF, homozygous for the Phe508del CFTR mutation
Interventions
Lumacaftor/ivacaftor treatment (LUMA/IVA).
Outcome measures
At the beginning and conclusion of the follow-up, all subjects received a modified 3 h OGTT, sampling at baseline, and at 30 min intervals for plasma glucose, serum insulin, and c-peptide concentrations to evaluate glucose tolerance, and quantify by modeling beta-cell insulin secretion responsiveness to glucose, insulin clearance and insulin sensitivity.
Main results
LUMA/IVA did not produce differences in glucose tolerance, insulin secretory parameters, clearance and sensitivity with respect to matched controls over one-year follow-up.
Authors' conclusions
We found no evidence of improvements in glucose tolerance mechanisms in patients with CF after one-year treatment with LUMA/IVA.